Novartis Announced Earlier, Investigational Atrasentan Phase III Study Demonstrates Clinically Meaningful And Highly Statistically Significant Proteinuria Reduction In Patients With IGA Nephropathy; Phase III ALIGN Study Met Its Primary Endpoint
Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase III ALIGN study (NCT04573478) of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients with IgA